References
- Mitch W.E., Buffington G., Lemann J., Walser M. Progression of chronic renal failure: a simple method of estimation. Lancet 1976; 2: 1326–1331
- Rutherford W.E., Blonding J., Miller J.P., Grunwalt A.S., Vavra J.D. Chronic progressive renal disease. Rate of change of serum creatinine concentration. Kidney Int. 1977; 11: 62–70
- Klarh S., Schreiner G., Ichikawa I. The progression of renal disease. N. England J. Med. 1988; 318: 1657–1666
- Jacobson H.R., Klahr S. Chronic renal failure: pathophysiology and management. Lancet 1991; 333: 419–423
- Klarh S. Mechanisms of progression of chronic renal damage. J. Nephrology 1999; 12: 53–62
- Grupo Italiano di Studi Epidemiolodici in Nefrologia (GISEN). Renal function and requirement for dialysis nephropathy patients on long-term ramipril: Rein follow-up trial. The Lancet 1998; 352: 1252–1256
- Mazouz H., Kacso I., Ghazali A., El Esper N., Morinieri P, Makdassi R., Hardy P., Westeel P.F., Achard J.M., Pruna A., Fournier A. Risk factors of renal failure progression two years prior to dialysis. Clinical Nephrology 1999; 51: 355–366
- Lun˘o J., García Vinuesa S., Gómez Campdera S., Lorenzo I., Rodríguez P., Dall'Anesse C., Rodríguez A., Valderrabano F. Factores predictivos en la progresión de la enfermedad renal. Nefrologia XIX 1999; 523–531
- Ruggenenti P., Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M., Scolari F., Schena F.P., Remuzzi G. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. The Lancet 1999; 354: 559–364
- Hannedouche T., Albooze G., Chauveau P., Lacour B., Jungers P. Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure. Am. J. Kidney Dis. 1993; 21(suppl 2)131–137
- Preston R.A., Fernandez L. Managing hypertension in patients with kidney disease implications for preservation of renal function. Am. J. Therapy 1998; 5: 355–362
- Hunscker L.G., Adler S., Caggiula A., England B.K., Greene T., Kusek J.W., Rogers N.L., Teschan P.E. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int. 1997; 51: 1908–1919
- Pereira B.J.G. Optimization of pre-ESRD care: the key to improve dialysis outcomes. Kidney Int. 2000; 57: 351–365
- Peterson J.C., Adler S., Burkart L.M., Greene T., Hebbert L.A., Hunsicker L.G., King A.J., Klahr S., Massry S.G., Seifter J.L. Blood pressure control, proteinuria and the progression of renal disease. The modification of diet in renal disease study. Ann. Int. Med. 1995; 123: 754–762
- Fabris B., Candido R., Armini L., Fischeti F., Calci M., Bardelli M., Fazio M., Campanacci L., Carreta R. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. J. Hypertension 1999; 17: 1925–1931
- Bakris G.L., Weir M.R. Angiotensin-converting enzyme inhibitor associated elevations in serum creatinine: is this a cause for concern?. Arch. Int. Med. 2000; 13: 685–693
- Samuelsson O., Mulec H., Knight Gibson C., Attman P.Q., Kron R., Larsson R., Weis H., Wedel H., Alaupovic P. Lipoprotein abnormalities are associated with increase rate of progression of human chronic renal insufficiency. Nephrol. Dial. Transplant. 1997; 12: 1908–1915